According to the latest report by IMARC Group, titled "North America Dry Eye Syndrome Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028," the North America dry eye syndrome market reached a value of US$ 2.5 Billion in 2022. Dry eye syndrome is a medical condition wherein the patient experiences a lack of lubrication or moisture on the surface of their eyes. Also known as keratoconjunctivitis sicca (KCS), it is a commonly occurring syndrome in ophthalmology. Some of the most common symptoms of dry eyes include itchy eyes, burning sensation, inflammation, redness, aching sensations, blurred vision, heaviness, fatigue, soreness, dryness and photophobia. Apart from this, watery eyes can also represent a major symptom for the condition as the eyes may over-stimulate the production of the watery component of tears in order to compensate for the dryness. The syndrome, however, is completely curable by medicines that are often marketed in the forms of gels, ointments and drops.
North America Dry Eye Syndrome Market Trends:
The market is primarily driven by the increasing reliance of the masses on electronic gadgets across the North American region. Smartphones, TVs, tablets and laptops are extensively utilized by individuals, especially students and working professionals. This has further received a boost due to the growing digitization across industries. In line with this, the prolonged usage of these digital devices has resulted in the increasing prevalence of numerous ocular disorders, including dry eye syndrome. Moreover, the rising incidences of numerous health conditions, such as diabetes, lupus, thyroid, scleroderma and rheumatoid arthritis, have led to an increase in the chances of developing dry eyes among patients as these diseases adversely affect the functioning patient’s tear glands. Furthermore, the steadily increasing geriatric population in the region is acting as another major growth-inducing factor. Elderly patients are more likely to develop ocular discomfort, which can result in the rising prevalence of this syndrome. Some of the other factors contributing to the market growth include growing awareness regarding the available treatment options and rapid advancements in the healthcare sector. On account of the aforementioned factors, the market is anticipated to reach a value of US$ 3.6 Billion by 2028, registering a CAGR of 5.8% during 2023-2028.
- On the basis of the disease type, the market has been divided into evaporative and aqueous dry eye syndrome.
- Based on the drug type, the market has been classified into lubricant eye drops, anti-inflammatory drugs, autologous serum eye drops and others.
- On the basis of the product, the market has been categorized into liquid drops, gels, liquid wipes, eye ointments and others.
- Based on the distribution channel, the market has been segmented into retail, hospital and online pharmacies.
- On the geographical front, the market has been bifurcated into the United States and Canada.
- The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
|Base Year of the Analysis
||Disease Type, Drug Type, Product, Distribution Channel, Country
||United States, Canada
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800